drugset
drugset / Trial / NCT03899909

A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects

NCT03899909 ↗

Phase 1 Completed 31 enrolled Lakefront Biotherapeutics NV
RandomizedSequentialQuadruple-blindBasic science

Summary

This study is a first-in-human, Phase I, randomized, double-blind, placebo controlled, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG3121 after oral single ascending doses (SAD) of GLPG3121 (part 1) and after oral multiple ascending doses (MAD) for 13 days of GLPG3121 (part 2) in healthy male subjects.

Timeline

Start
2019-03-29
Primary completion
2019-06-03
Completion
2019-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG3121 Unknown — Oral

Indications

No indication recorded.